Cedirogant (ABBV-157) is an orally active RORγt inverse agonist. Cedirogant can be used for psoriasis research.
IC50&Target
RORγt
体外研究
The transcription factor retinoic acid-related orphan receptor gamma t (RORγt) has been identified as the master regulator of TH17 cell differentiation and IL-17/22 production and is therefore an attractive target for the treatment of inflammatory diseases. Cedirogant (ABBV-157) has the potential for chronic plaque psoriasis research.
分子量
547.78
CAS号
2055496-11-0
运输条件
Room temperature in continental US; may vary elsewhere.